Ivonescimab plus chemotherapy in non–small cell lung cancer with EGFR variant
JAMA
About The Study: Ivonescimab plus chemotherapy significantly improved progression-free survival with tolerable safety profile in patients with non–small cell lung cancer who previously underwent EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment and may offer a new treatment option for patients with TKI resistance.
Quote from corresponding author Li Zhang, M.D.:
“For patients with non-small cell lung cancer whose illness has progressed while receiving EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, especially the third generation TKIs, optimal treatment options remain limited.
“This randomized, placebo-controlled phase 3 study demonstrated ivonescimab plus chemotherapy significantly improved progression-free survival (7.1 vs 4.8 months) compared with chemotherapy alone in TKI-treated non-small cell lung cancer.
“Based on the results of this study, ivonescimab has been approved in China as a new treatment option for those patients. An international multi-center study of this treatment regimen is ongoing.”
Contact information for Li Zhang, M.D.: email zhangli@sysucc.org.cn.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2024.10613)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.10613?guestAccessKey=4a907c26-6d2e-46e7-94b1-d0b5670ff18a&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=053124
END
Quote from corresponding author Li Zhang, M.D.:
“For patients with non-small cell lung cancer whose illness has progressed while receiving EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, especially the third generation TKIs, optimal treatment options remain limited.
“This randomized, placebo-controlled phase 3 study demonstrated ivonescimab plus chemotherapy significantly improved progression-free survival (7.1 vs 4.8 months) compared with chemotherapy alone in TKI-treated non-small cell lung cancer.
“Based on the results of this study, ivonescimab has been approved in China as a new treatment option for those patients. An international multi-center study of this treatment regimen is ongoing.”
Contact information for Li Zhang, M.D.: email zhangli@sysucc.org.cn.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2024.10613)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.10613?guestAccessKey=4a907c26-6d2e-46e7-94b1-d0b5670ff18a&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=053124
END